FREQUENTLY ASKED QUESTIONS

InMode’s device portfolio is primarily focused on radiofrequency (RF) technology — a form of electromagnetic energy that generates controlled heat in tissue to stimulate collagen remodeling, tighten skin, reduce fat, and promote tissue contraction. In addition to RF, InMode’s platforms also incorporates intense pulsed light (IPL), laser, CO2, and electrical muscle stimulation (EMS) in select devices.

InMode utilizes several distinct RF modalities across its product line:

• Bipolar RF — Delivers energy between two electrodes with controlled depth, used in non-invasive skin tightening and rejuvenation treatments
• RF-Assisted Lipolysis (RFAL) — InMode’s proprietary approach to minimally invasive body and face contouring, where RF energy is delivered internally to simultaneously liquify fat and contract tissue from within
•  Deep Subdermal Fractional RF — Delivers RF energy through microneedles at adjustable depths, combining microneedling with volumetric RF heating for skin remodeling
•  Monopolar RF — Used in select platforms for deeper tissue heating across larger treatment areas

The clinical advantage of RF-based technology is its versatility. RF energy can address skin laxity, fat reduction, and textural improvement within a single treatment platform. RF also has a well-documented safety profile across all Fitzpatrick skin types (I-VI), making it applicable to a broader patient population than some laser and light-based alternatives.

InMode’s device portfolio is primarily focused on radiofrequency (RF) technology — a form of electromagnetic energy that generates controlled heat in tissue to stimulate collagen remodeling, tighten skin, reduce fat, and promote tissue contraction. In addition to RF, InMode’s platforms also incorporates intense pulsed light (IPL), laser, CO2, and electrical muscle stimulation (EMS) in select devices.

InMode utilizes several distinct RF modalities across its product line:

• Bipolar RF — Delivers energy between two electrodes with controlled depth, used in non-invasive skin tightening and rejuvenation treatments
• RF-Assisted Lipolysis (RFAL) — InMode’s proprietary approach to minimally invasive body and face contouring, where RF energy is delivered internally to simultaneously liquify fat and contract tissue from within
• Deep Subdermal Fractional RF — Delivers RF energy through microneedles at adjustable depths, combining microneedling with volumetric RF heating for skin remodeling
•  Monopolar RF — Used in select platforms for deeper tissue heating across larger treatment areas

The clinical advantage of RF-based technology is its versatility. RF energy can address skin laxity, fat reduction, and textural improvement within a single treatment platform. RF also has a well-documented safety profile across all Fitzpatrick skin types (I-VI), making it applicable to a broader patient population than some laser and light-based alternatives.

InMode holds [INSERT: exact number] FDA clearances spanning multiple device platforms and treatment indications. These clearances cover a range of non-invasive and minimally invasive technology for soft tissue contraction, dermal remodeling, fat disruption, and skin resurfacing.

Notable clearances include Morpheus8’s 2024 FDA clearance for soft tissue contraction — the first and only clearance of its kind for a fractional radiofrequency microneedling device. InMode’s RFAL technology (used in BodyTite, FaceTite, and AccuTite) hold FDA clearances for electrocoagulation and hemostasis. The EmpowerRF platform holds clearances related to neuromuscular re-education for women’s wellness applications.

FDA clearance is a meaningful differentiator in aesthetic device selection because it requires submission of clinical safety and performance data to the U.S. Food and Drug Administration. Providers should verify that any aesthetic device they purchase holds FDA clearance for the specific indications they intend to treat. InMode’s clinical affairs team can provide documentation of all current clearances upon request.

InMode’s technologies are supported by over 100 peer-reviewed publications across dermatology, plastic surgery, gynecology, and ophthalmology journals. These studies cover clinical outcomes, safety profiles, histological analysis, and patient satisfaction data for InMode’s RF, RFAL, fractional RF microneedling, and IPL platforms.

The depth of clinical evidence varies by product maturity. Morpheus8 and BodyTite have the most extensive published literature, with studies examining treatment efficacy across multiple indications, skin types, and patient demographics. Newer platforms have emerging clinical data with additional studies in progress.

Providers can access the full clinical paper library at https://inmodeuniversity.com/clinical-papers/ and consult with InMode’s clinical team for studies relevant to specific treatment applications.

InMode devices are available in over 100 countries across North America, Europe, the Middle East, Asia-Pacific, and Latin America. The company maintains direct sales operations in the United States, Canada, the United Kingdom, Ireland, France, Germany, Italy, Spain, Portugal, Belgium, Luxembourg, Austria, Japan, Australia, and India, with authorized distributors serving additional markets.

InMode’s global presence is significant for practitioners across diverse patient populations, skin types, and regulatory environments. Clinical data published from international sites provides a broader evidence base than studies conducted in a single market. InMode’s regional offices also provide localized training, service, and support to ensure consistent outcomes regardless of geography.

The right InMode platform depends on three factors: your clinical specialty, the treatment categories your patients demand, and how the device fits into your existing or planned service menu.

InMode’s portfolio is organized into workstation platforms, each designed around specific treatment categories:

• Face contouring and rejuvenation — Define, Morpheus8, FaceTite (via IgniteRF)
• Body contouring and skin tightening — EvolveX (non-invasive), BodyTite (minimally invasive, via IgniteRF)
• Skin resurfacing — Solaria (fractional CO2), Morpheus8 (fractional RF)
• Multi-application (face + body + vascular + hair removal) — OptimasMAX
• Women’s wellness — EmpowerRF
• Eye care — Envision
• Hair removal — Triton
• Circulatory wellness — ApexRF

InMode’s sales and clinical teams offer practice consultations to help match platform selection to your specialty, patient demographics, and business goals. Visit each product’s dedicated page on this site for detailed specifications, clinical evidence, and treatment applications.

Yes. InMode’s workstation architecture is designed around a base platform with interchangeable handpieces and applicators, allowing a single device to deliver multiple treatment modalities. This is a fundamental design principle across InMode’s product line and a key economic advantage for practices.

Examples of multi-treatment capability:

• IgniteRF includes handpieces for FaceTite (facial contouring), BodyTite (body contouring), AccuTite (precision small-area treatment), and Morpheus8 (fractional RF microneedling) — all from one workstation
• OptimasMAX combines fractional RF, IPL, and laser capabilities for face treatments, body treatments, hair removal, and vascular applications
• EmpowerRF integrates VTone, FormaV, and Morpheus8V for a comprehensive women’s wellness treatment protocol
• EvolveX offers Tite (skin tightening), Tone (muscle stimulation), and Trim (fat reduction) in a single hands-free platform

This multi-modality approach allows practices to expand their treatment menu without purchasing separate devices for each service category.

InMode devices are used across a broader range of medical specialties than most aesthetic device manufacturers serve. Current InMode users include:

• Plastic surgeons — Face and body contouring, skin tightening, RFAL procedures (BodyTite, FaceTite, Morpheus8)
• Dermatologists — Skin rejuvenation, resurfacing, pigment and vascular treatment, acne scarring (Morpheus8, Lumecca, Solaria)
• MedSpa owners and operators — Non-invasive face and body treatments, hair removal (EvolveX, Forma, DiolazeXL, Triton)
• OB/GYN and urogynecology — Women’s wellness treatments including pelvic floor strengthening and vaginal rejuvenation (EmpowerRF: VTone, FormaV, Morpheus8V)
• Ophthalmologists and optometrists — Dry eye disease and meibomian gland dysfunction treatment (Envision: Forma-I, Lumecca-I)
• ENT specialists — Select facial aesthetic applications

This multi-specialty reach means InMode’s clinical evidence base is informed by practitioners across different disciplines and patient populations. It also means that training and best practices are developed from a broader clinical perspective than manufacturers who serve a single specialty. Providers benefit from cross-specialty insights — for example, RF tissue interaction data from plastic surgery informs dermatological applications, and vice versa.

No. InMode devices are professional-grade, FDA-cleared medical devices designed exclusively for use by licensed healthcare providers and trained practitioners in clinical settings. They are not available for personal or home use.

InMode’s devices deliver energy at therapeutic levels that require clinical training to apply safely and effectively. The power output, depth of tissue penetration, and treatment parameters of professional devices significantly exceed what consumer-grade devices offer — which is what enables the clinical outcomes InMode’s platforms are known for, but also why proper training and clinical oversight are necessary.

Consumers interested in InMode treatments should use the Find a Provider tool at https://www.inmodemd.com/find-a-provider to locate a trained InMode provider in their area. Providers interested in purchasing InMode devices can contact InMode’s sales team for a consultation.

InMode University is InMode’s continuing education platform for current device owners and their clinical staff. It extends beyond initial device training to support long-term skill development, protocol optimization, and clinical confidence.

InMode University resources include:

• Advanced technique workshops — Hands-on sessions covering advanced treatment protocols, combination therapies, and clinical tips from experienced InMode practitioners
• Online education modules — [INSERT: details on digital learning platform, webinars, or on-demand content available through InMode University]
• Peer-to-peer learning — Opportunities to learn from experienced InMode providers through case presentations, clinical forums, and regional events
• New indication training — As InMode expands its technology portfolio and secures additional FDA clearances, InMode University provides training on new treatment applications for existing device owners [INSERT: any CE credit availability, accreditation details, or partnership with medical education organizations]

Ongoing clinical education matters because aesthetic technology evolves rapidly. Treatment techniques, combination protocols, and patient selection criteria improve as more clinical data becomes available. InMode University ensures that providers stay current with the latest evidence-based approaches to InMode treatments, which directly impacts patient outcomes and practice reputation.

Yes. InMode offers several pathways for providers to experience its technologies and access educational content before making a purchase commitment:

• In-office demonstrations — InMode’s sales and clinical teams can arrange a device demonstration at the provider’s practice, allowing hands-on experience with the technology in the provider’s own clinical environment
• Clinical events and workshops — InMode hosts regional and national educational events where providers can observe live treatments, attend technique presentations, and speak with experienced InMode users.
• Clinical paper library — InMode’s published clinical evidence is publicly accessible at https://inmodeuniversity.com/clinical-papers/, allowing providers to review outcomes data, safety profiles, and treatment protocols before making a purchase decision

InMode’s approach is to give providers the clinical confidence and economic clarity needed to make an informed device decision. The sales process is consultative — focused on matching the right technology to the right practice — rather than transactional.

InMode provides comprehensive technical support and field service coverage to all device owners across the United States and its international direct markets.

Service and support infrastructure includes:

• [INSERT: service response time — e.g., “24-48 hour response time for service requests”]
• [INSERT: field service details — e.g., “X field service engineers across the US” or “nationwide service van fleet”]
• Remote diagnostics — [INSERT: details on remote diagnostic capabilities, if available]
• Warranty coverage — [INSERT: standard warranty terms and what they include]
• Extended service contracts — [INSERT: details on optional extended warranty/service plans]
• Software updates — [INSERT: policy on firmware and software updates for existing devices]
• Parts and consumables — [INSERT: how providers order replacement parts and consumables — direct from InMode vs. authorized distributors]

Reliable post-purchase service directly impacts practice economics. Device downtime means lost revenue and rescheduled patients. When evaluating aesthetic device manufacturers, providers should ask specific questions about service response times, warranty terms, field service coverage in their area, and whether remote diagnostics can resolve issues without an on-site visit.

Contact InMode’s service team at 855.411.2639 or email customercare@inmodemd.com for service coverage specific to your location.

The rapid adoption of GLP-1 receptor agonist medications (such as semaglutide and tirzepatide) for weight loss is creating a significant and growing patient population with specific aesthetic concerns that energy-based devices are well-positioned to address.

Patients who experience substantial weight loss — whether through GLP-1 medications, bariatric surgery, or other means — frequently present with:

• Skin laxity — Rapid fat volume loss outpaces the skin’s ability to contract, leaving loose or sagging skin on the face, neck, arms, abdomen, and thighs
• Muscle tone reduction — Some GLP-1 patients experience muscle mass loss alongside fat loss, affecting body composition and contour
• Facial volume loss — Colloquially called “Ozempic face,” the loss of facial fat volume can create a gaunt or aged appearance
• Contour irregularities — Uneven fat reduction can leave areas of textural inconsistency

Energy-based aesthetic technologies directly address these concerns. RF-based skin tightening (non-invasive and minimally invasive) can help contract lax tissue without surgery. Muscle stimulation technologies can address tone loss. Fractional RF microneedling can improve skin texture and stimulate collagen production in areas affected by rapid volume change.

For practices, the GLP-1 patient represents a new and growing treatment demographic. These patients are already invested in their body transformation and are often highly motivated to address the aesthetic concerns that weight loss alone does not resolve. Practices with a range of non-invasive through minimally invasive technologies can build multi-treatment protocols tailored to post-weight-loss patients.

[INSERT: Any specific InMode clinical data or protocols related to post-weight-loss patients, GLP-1 body contouring, or relevant published studies]